Prognostication Following Transcatheter Edge-to-Edge Mitral Valve Repair Using Combined Echocardiography-Derived Velocity Time Integral Ratio and Artificial Intelligence Applied to Electrocardiogram.

IF 3 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Nadera N Bismee, Isabel G Scalia, Mohammed Tiseer Abbas, Juan M Farina, Milagros Pereyra Pietri, Kamal Awad, Nima Baba Ali, Niloofar Javadi, Sogol Attaripour Esfahani, Hesham Sheashaa, Omar H Ibrahim, Fatmaelzahraa E Abdelfattah, F David Fortuin, Steven J Lester, John P Sweeney, Chadi Ayoub, Reza Arsanjani
{"title":"Prognostication Following Transcatheter Edge-to-Edge Mitral Valve Repair Using Combined Echocardiography-Derived Velocity Time Integral Ratio and Artificial Intelligence Applied to Electrocardiogram.","authors":"Nadera N Bismee, Isabel G Scalia, Mohammed Tiseer Abbas, Juan M Farina, Milagros Pereyra Pietri, Kamal Awad, Nima Baba Ali, Niloofar Javadi, Sogol Attaripour Esfahani, Hesham Sheashaa, Omar H Ibrahim, Fatmaelzahraa E Abdelfattah, F David Fortuin, Steven J Lester, John P Sweeney, Chadi Ayoub, Reza Arsanjani","doi":"10.3390/jpm15080371","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction</b>: Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as a minimally invasive option for high-risk surgical candidates with severe and symptomatic mitral regurgitation (MR), but post-procedure residual mitral valve (MV) dysfunction remains a significant concern. This study evaluates the clinical utility of combining artificial intelligence applied to electrocardiograms (ECG-AI) for diastolic dysfunction (DD) grading and the echocardiography-derived velocity time integral of the MV and left ventricular outflow tract ratio (VTI<sub>MV</sub>/<sub>LVOT</sub>) in predicting prognosis in patients post-M-TEER. <b>Methods</b>: A retrospective analysis of patients who underwent M-TEER between 2014 and 2021 was conducted. Patients were categorized based on VTI<sub>MV/LVOT</sub> and ECG-AI scores into three groups: both normal parameters, either abnormal parameter, or both abnormal parameters to compare outcomes (mortality, major adverse cardiovascular events [MACE], and the need for subsequent MV reintervention) using Kaplan-Meier analysis, multivariable Cox regression models, and net reclassification improvement. <b>Results</b>: Overall, 250 patients were included; the median age was 79.5 (IQR: 73.1, 84.6) and 66.4% were male. The combined abnormal VTI<sub>MV/LVOT</sub> (≥2.5) and ECG-AI score for DD (>1) was associated with higher risk of one-year mortality (adjusted HR: 4.56 [1.04-19.89], <i>p</i> = 0.044) and MACE (adjusted HR: 3.72 [1.09-12.72], <i>p</i> = 0.037) compared to patients with both normal parameters. <b>Conclusions</b>: This study highlights the potential additive value of integrating VTI<sub>MV/LVOT</sub> and ECG-AI scores as a prognostic tool for a personalized approach to the post-operative evaluation and risk stratification in M-TEER patients.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 8","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12387676/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15080371","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as a minimally invasive option for high-risk surgical candidates with severe and symptomatic mitral regurgitation (MR), but post-procedure residual mitral valve (MV) dysfunction remains a significant concern. This study evaluates the clinical utility of combining artificial intelligence applied to electrocardiograms (ECG-AI) for diastolic dysfunction (DD) grading and the echocardiography-derived velocity time integral of the MV and left ventricular outflow tract ratio (VTIMV/LVOT) in predicting prognosis in patients post-M-TEER. Methods: A retrospective analysis of patients who underwent M-TEER between 2014 and 2021 was conducted. Patients were categorized based on VTIMV/LVOT and ECG-AI scores into three groups: both normal parameters, either abnormal parameter, or both abnormal parameters to compare outcomes (mortality, major adverse cardiovascular events [MACE], and the need for subsequent MV reintervention) using Kaplan-Meier analysis, multivariable Cox regression models, and net reclassification improvement. Results: Overall, 250 patients were included; the median age was 79.5 (IQR: 73.1, 84.6) and 66.4% were male. The combined abnormal VTIMV/LVOT (≥2.5) and ECG-AI score for DD (>1) was associated with higher risk of one-year mortality (adjusted HR: 4.56 [1.04-19.89], p = 0.044) and MACE (adjusted HR: 3.72 [1.09-12.72], p = 0.037) compared to patients with both normal parameters. Conclusions: This study highlights the potential additive value of integrating VTIMV/LVOT and ECG-AI scores as a prognostic tool for a personalized approach to the post-operative evaluation and risk stratification in M-TEER patients.

Abstract Image

超声心动图速度积分比与人工智能联合应用于心电图的二尖瓣边缘修复术后预测。
二尖瓣经导管边缘到边缘修复(M-TEER)已成为一种微创选择,用于高危手术候选人严重和症状性二尖瓣反流(MR),但术后残留二尖瓣功能障碍仍然是一个重要的问题。本研究评估了人工智能应用于心电图(ECG-AI)的舒张功能障碍(DD)分级和超声心动图衍生的MV和左心室流出道比(VTIMV/LVOT)的速度时间积分在预测m - teer后患者预后中的临床应用。方法:回顾性分析2014年至2021年间接受M-TEER治疗的患者。根据VTIMV/LVOT和ECG-AI评分将患者分为三组:正常参数组、异常参数组或异常参数组,使用Kaplan-Meier分析、多变量Cox回归模型和净再分类改善来比较结果(死亡率、主要心血管不良事件[MACE]和后续MV再干预的需要)。结果:共纳入250例患者;中位年龄为79.5岁(IQR: 73.1, 84.6), 66.4%为男性。与两项指标均正常的患者相比,VTIMV/LVOT(≥2.5)和ECG-AI评分(>1)联合异常的患者一年死亡风险较高(校正HR: 4.56 [1.04-19.89], p = 0.044)和MACE(校正HR: 3.72 [1.09-12.72], p = 0.037)。结论:本研究强调了整合VTIMV/LVOT和ECG-AI评分作为M-TEER患者术后评估和风险分层个性化方法的预后工具的潜在附加价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Personalized Medicine
Journal of Personalized Medicine Medicine-Medicine (miscellaneous)
CiteScore
4.10
自引率
0.00%
发文量
1878
审稿时长
11 weeks
期刊介绍: Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信